The 'Psychedelic' Problem: Why Nobody Can Agree on What to Call This Industry

In January 2026, two prominent companies in psychedelic medicine rebranded around the language of pharma and psychiatry.

Cybin — a company built on psilocybin research — began operating as Helus Pharma. Its new ticker: NASDAQ: HELP. MindMed became Definium Therapeutics. Definium’s announcement still used the word “psychedelic”; Helus’s did not. The new identities led with “pharma,” “therapeutics,” and “psychiatry.”

This was not a coincidence. It was a strategy.

The industry that built itself around a word is now running from it. The words we choose determine who gets money, who gets prescribed, who gets arrested, and who gets listened to.

Why Are Psychedelic Companies Ditching the Word “Psychedelic”?

The rebrands happened fast. Cybin began operating as Helus Pharma and trading under HELP; MindMed followed as Definium Therapeutics. Two major players made the same decision in the same month.

The stated reasons were corporate boilerplate: expanded pipelines, positioning for growth. The unstated reasons are more interesting.

Here’s the investor problem — my read of the incentives, not documented policy: when “psychedelic” appears on a NASDAQ filing, some institutional investors can’t touch it. ESG funds have compliance frameworks. Conservative portfolios have risk screens. Pension managers have boards to answer to. The word itself triggers review processes that “neuroscience” and “therapeutics” do not.

Then there’s the regulatory problem. The DEA doesn’t care what you call your company. Psilocybin and MDMA are still Schedule I under federal law — a category for drugs the government says have a high potential for abuse, no currently accepted medical use, and no accepted safety for use under medical supervision. A name change doesn’t change a molecule or its legal status. The FDA reviews the evidence either way, but the framing still shapes how investors, clinicians, and the public hear the treatment. “Psychedelic therapy” puts you next to recreational users. “A novel therapeutic compound” puts you next to Pfizer.

You can change your name. You can’t change your Schedule I listing.

The rebrand isn’t cosmetic. It’s regulatory strategy, investor relations, and clinical positioning in one move. These companies aren’t embarrassed by what they do — they’re trying to survive the pipeline from clinical trials to market, and every word in that pipeline gets scrutinized.

The Word Nobody Wants to Say (And Everybody Searches For)

Here’s the catch: “psychedelic” is the word people actually type into Google. “Entheogen” — not so much. The word the industry is fleeing is the word the public uses to find it.

This creates a painful split. Companies can’t use the word in investor decks, but they need it for search visibility, media coverage, and public education. They’re speaking two languages — one for Wall Street and one for everyone else.

We’ve seen this before. The cannabis industry went through the same crisis. For decades, “marijuana” was the legal term and “weed” was what everyone called it. Then the industry standardized on “cannabis” — clinical, botanical, respectable. Dispensaries became “wellness centers.” Products became “flower” instead of “pot.” The language got sanitized for regulators and investors while the culture kept saying “weed.”

The cannabis parallel isn’t perfect. Cannabis had decades of counterculture baggage to shed before institutional money could flow. Psychedelics are earlier in that process. But the pattern is identical: an emerging industry needs institutional legitimacy, so it polices its language. The gap between what the industry calls itself and what everyone else calls it signals who’s inside and who’s outside.

There’s one difference that matters. Cannabis had a way out — “cannabis” was already the botanical term, sitting right there in the scientific literature. The psychedelic industry doesn’t have one. No single clinical word replaces “psychedelic” without losing something. Nobody searches for “hallucinogen-assisted therapy.” “Serotonergic psychedelic” is technically precise and completely unmarketable. The field is stuck between a word that works and words that don’t.

Michael Pollan’s How to Change Your Mind — a number-one New York Times bestseller in 2018 — mainstreamed the word “psychedelic” for a general audience. It made the word safe for dinner table conversation. The companies commercializing what he wrote about are now dropping it.

But the companies building actual products are moving away from the language people use and toward “neuroscience,” “therapeutics,” and “neuropsychiatry.” The gap between what people call this field and what the field calls itself keeps growing.

What Do We Actually Call This? A Field Guide to the Language

There is no neutral term — every word carries a position.

Let’s walk through the major ones.

Psychedelic. Coined in 1956 by psychiatrist Humphry Osmond, who combined Greek words for “mind” and “to manifest,” and introduced publicly in 1957. It’s the most recognized term — the one general audiences actually use. It’s also the word most loaded with cultural baggage — 1960s counterculture, DEA Schedule I, Timothy Leary.

Psychedelic-assisted therapy (PAT). The clinical workhorse. The word “assisted” does enormous work here — it positions the substance as a tool within therapy, not a treatment on its own. This is the term clinicians, researchers, and regulators use. It’s precise, professional, and deliberately unsexy.

Plant medicine. Popular in wellness circles. Sounds natural and gentle. But it’s imprecise — MDMA (an entactogen) and ketamine (a dissociative anesthetic), two of the most studied substances in this field, are synthetic. Neither is a plant, and psilocybin comes from fungi, not plants. Calling them “plant medicine” is like calling a pharmaceutical a “tea.”

Entheogen. Used by spiritual and religious communities. Scholars — Carl Ruck, Jeremy Bigwood, Danny Staples, Jonathan Ott, and R. Gordon Wasson — coined it in 1979 to emphasize the sacred: “generating the divine within.” The substances carry deep cultural weight in Indigenous traditions where they’ve been used for centuries; the word itself is modern, and not every tradition uses it. It also alienates secular and clinical audiences who need precisely the kind of legitimacy this field is fighting for. You won’t see “entheogen” in an FDA filing. You’ll see it in ceremony.

Hallucinogen. The DEA still uses this one; the FDA uses it alongside “psychedelic drugs,” including in its July 2026 clinical guidance. It’s pharmacologically broad. “Hallucination” implies the experience isn’t real. Critics read the word as pathologizing by design — that’s interpretation, not documented history.

Novel therapeutic compound. What pharmaceutical companies and investors say. Clean. Regulatory-friendly. Deliberately vague. This is the language of earnings calls and early pipeline decks.

Here’s how they stack up:

Term	Who Uses It	Connotation	Baggage	Best For
Psychedelic	General public, media, researchers	Familiar, mind-expanding	1960s counterculture, Schedule I stigma	Search visibility and general audience writing
Psychedelic-assisted therapy (PAT)	Clinicians, researchers, treatment providers	Medical, structured, professional	Can make the drug sound secondary and the experience too tidy	Clinical and professional contexts
Plant medicine	Wellness and ceremonial communities	Natural, traditional, gentle	Does not fit synthetic drugs like MDMA or ketamine	Contexts involving plant-derived substances
Entheogen	Spiritual and religious communities	Sacred, ceremonial	Can alienate secular audiences; not universal across traditions	Religious liberty, ceremonial, and cultural contexts
Hallucinogen	Federal agencies, older research literature	Clinical, drug-class framing	Reduces the experience to hallucination; broad by definition	Regulatory language and some research contexts
Novel therapeutic compound	Pharmaceutical companies, investors	Institutional, regulatory-friendly	Deliberately vague; says little about experience or mechanism	Investor materials and early pipeline descriptions
Emerging mental health treatment	Policymakers, mainstream media	Accessible, non-threatening	Too vague for search; does not identify the treatment	High-level public and policy communication
Psychedelic medicine	Clinicians, media, public-facing organizations	Professional but accessible	Can blur research, approved care, and underground practice	General audience writing with a clinical frame

There’s a deeper problem hiding in this table. Indigenous communities used these substances for centuries before “psychedelic” existed as a word. At the 2025 Indigenous Ayahuasca Conference, representatives from 34 Indigenous peoples called for protection of traditional knowledge and opposed its exploitation without consultation and consent. Companies have filed patents touching therapist behavior around these substances — filing is not owning; applications and granted claims vary by jurisdiction. Then they rebrand to scrub any trace of the word “psychedelic” from their corporate identity. The erasure is twofold. First the practices get extracted. Then the language gets cleaned up so nobody has to think about where they came from.

Every term in that table is a choice with consequences. There is no word you can use that doesn’t take a side.

Why the Words We Choose Matter

This isn’t an academic argument about semantics. Language drives outcomes.

Who gets funding. Institutional investors are likely more comfortable buying stock in “Definium Therapeutics” than “MindMed” — that’s an inference from how these systems work, not a documented rule. ESG compliance frameworks, risk committees, investment policy statements — all of these can filter by language before they filter by science. A pension fund manager might not be able to justify a position in a “psychedelic company” to their board. That same manager can buy “a neuroscience therapeutics company” without a second conversation. Same molecule. Different cover sheet.

Who gets prescribed. A doctor is more likely to recommend “psychedelic-assisted therapy” than “psychedelic therapy.” That one word — “assisted” — reframes the substance from treatment to tool. It tells the doctor: you still matter. The therapy is yours. The substance is just something that helps. That framing matters in clinical adoption.

Who gets arrested. Law enforcement doesn’t distinguish between “entheogen” and “psilocybin.” Your word choice doesn’t change your legal status. But the word a lawmaker uses in a bill determines what’s legal. Minnesota’s HF 2906 — the standalone psilocybin bill that stalled in committee — talks about “psilocybin mushrooms” and references the state’s Psychedelic Medicine Task Force. The industry is already moving away from that language. That gap between legislative language and corporate language will matter as more states write bills.

Who gets listened to. The patient who calls it “medicine” gets treated differently than the patient who calls it “drugs.” The researcher who says “novel therapeutic compound” gets a different hearing than the one who says “psychedelic.” Same substances. Same science. Different reception based on the words wrapping the work.

The words don’t change the molecule. But they change everything around it.

What Happens Next: An Industry That Can’t Name Itself

The rebranding will continue. Other companies will follow Helus Pharma and Definium Therapeutics. Corporate names, investor decks, and pipeline descriptions will keep favoring words like “therapeutics,” “psychiatry,” and “neuroscience.” Once a company makes that shift, there’s little incentive to reverse it.

But the word won’t disappear from search bars, news headlines, or everyday conversation. The gap between corporate language and human language will widen. Companies will speak clinical. People will speak psychedelic.

The companies that figure out how to bridge that gap — to speak to regulators in their language and to humans in ours — will be the ones that break through. Not because they picked the right word. Because they understood that every audience needs its own language.

The problem isn’t the word. The problem is pretending the word doesn’t matter.

Frequently Asked Questions About Psychedelic Terminology